Rigel Pharmaceuticals Inc. (New) Stock Prediction
AI-powered sentiment analysis and prediction trends for RIGL, updated each market day.
RIGL AI Sentiment
AI predicts Rigel Pharmaceuticals Inc. (New) stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Sector
Exchange
Market Cap
$563,825,379
Cap Tier
Employees
174
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Nov. 29, 2000
Website
RIGL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RIGL Volatility
Rigel Pharmaceuticals Inc. (New) has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
